Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Musumeci, A. Banfi, G. Blois, G. Candiani, G. DePalo, F. DiRe, et al.
Lymphangiography in patients with ovarian epithelial cancer: an evaluation of 289 cases.
Cancer, 40 (1977), pp. 1444-1449
[2.]
P. Dvorestsky, K. Richards, C. Angel, L. Rabinowitz, M. Stoler, J. Beecham, et al.
Distribution of desease at autopsy in 100 women with ovarian cancer.
Hum Pathol, 19 (1988), pp. 57-63
[3.]
H. Abrams, R. Spiro, N. Goldstein.
Metastases in carcinoma: analysis of 1000 autopsied cases.
Cancer, 3 (1950), pp. 74-85
[4.]
E. Burghardt, F. Girardi, M. Lahousen, K. Tamussino, H. Stettner.
Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer.
Gynecol Oncol, 40 (1991), pp. 103-106
[5.]
S. Kehoe, D. Luesley, T. Rollason.
Ovarian carcinoma presenting with inguinal metastatic lymphadenopathy 33 months prior to intrabdominal disease.
Gynecol Oncol, 50 (1993), pp. 128-130
[6.]
K. McGonigle, M. Dudzinski.
Endometrioid carcinoma of the ovary presenting with an enlarged inguinal lymph node without evidence of abdominal carcinomatosis.
Gynecol Oncol, 45 (1992), pp. 225-228
[8.]
R. Yancik, L. Ries, J. Yates.
Ovarian cancer in the elderly: an analysis of surveillance, epidemiology and end results program data.
Am J Obstet Gynecol, 154 (1986), pp. 639-647
[9.]
R. Hightower, H. Nguyen, H. Averette, W. Hoskins, T. Harrison, A. Steren.
National survey of ovarian carcinoma IV: patterns of care and related survival for older patients.
Cancer, 73 (1994), pp. 377-383
[10.]
A. Bicher, G. Sarosy, E. Kohn, D. Adamo, P. Davis, J. Jacob, et al.
Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.
Cancer, 71 (1993), pp. 594-600
[11.]
T. Cornelison, E. Reed.
Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age.
Cancer, 71 (1993), pp. 650-655
[12.]
NIH Consensus conference ovarian Cancer.
Screening, treatment and follow-up.
Jama, 273 (1995), pp. 491-497
[13.]
The early breast cancer trialists' collaborative group.
Lancet, 351 (1998), pp. 1451-1467
[14.]
F. Bonilla, F. Pérez-López.
Cáncer de mama, 1.a ed, pp. 17-32
[15.]
J. Boyd, Y. Sonoda, M. Federici, F. Bogomolniy, E. Rhei, D. Maresco, et al.
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
Jama, 283 (2000), pp. 2260-2265
[16.]
S. Thorlacius, J. Struewing, P. Hartge, G. Olafsdottir, H. Sigvaldason, L. Tyggvadottir, et al.
Population-based study of risk of breast cancer in carriers of BRCA2 mutation.
Lancet, 352 (1998), pp. 1337-1339
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia